bp(GO:"GO:0007271")

Entity

Name

GO:0007271

Namespace

go

Namespace Version

20180828

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/go.belns

ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly PubMed:16273023

Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning PubMed:16273023

Glutamatergic and cholinergic abnormalities are strongly correlated with cognitive deterioration in Alzheimer's disease, and both types of abnormalities have been hypothesized to have a causative role in this deterioration. The two major classes of agents used to treat cognitive symptoms of Alzheimer's disease are ChEIs and NMDA receptor antagonists. PubMed:16273023

Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning PubMed:16273023

Despite a putative beneficial role for increased CBF neuron alpha7 nAChR expression in AD (that may also be relevant to smoking behavior), evidence suggests that increased alpha7 nAChR expression contributes to cellular degeneration. Notably, alpha7 nAChR binds and/or interacts with APP and Ab peptides [123–125]. Increased NB neuronal alpha7 nAChR expression may arise as a compensatory response that is offset by aberrant Ab-alpha7 nAChR interactions, leading to cholinergic dysfunction. PubMed:18986241

Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning PubMed:16273023

Glutamatergic and cholinergic abnormalities are strongly correlated with cognitive deterioration in Alzheimer's disease, and both types of abnormalities have been hypothesized to have a causative role in this deterioration. The two major classes of agents used to treat cognitive symptoms of Alzheimer's disease are ChEIs and NMDA receptor antagonists. PubMed:16273023

ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly PubMed:16273023